tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Hemogenyx Pharmaceuticals Expands Clinical Trial to Include Pediatric Patients

Story Highlights
  • Hemogenyx Pharmaceuticals expands its CAR-T cell therapy trial to include pediatric patients.
  • This trial expansion broadens the potential patient base and supports Hemogenyx’s growth.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Hemogenyx Pharmaceuticals Expands Clinical Trial to Include Pediatric Patients

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) just unveiled an update.

Hemogenyx Pharmaceuticals announced that the Institutional Review Board at MD Anderson Cancer Center has approved an amendment to their Phase I trial of HG-CT-1, a CAR-T cell therapy for relapsed or refractory acute myeloid leukemia, to include pediatric patients. This expansion marks a significant milestone, broadening the potential patient population and demonstrating the company’s commitment to advancing treatment options in the pediatric setting, which may enhance their market positioning and support long-term growth.

More about HemoGenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals is a clinical stage biopharmaceutical company, publicly traded on the London Stock Exchange, with headquarters in London and US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing several distinct product candidates and platform technologies for innovative product development.

Average Trading Volume: 129,460

Technical Sentiment Signal: Buy

Current Market Cap: £57.9M

Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1